Evidence map›Paper›PMID 42866320›Full record

ArticleFrontiers in microbiology2026

Genomic characteristics of a carbapenem-resistant NDM-1-producing

Zheng Bao, Zhenyu Mao, Yanye Tu

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zheng BaoDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital of Ningbo University, Ningbo, Zhejiang, China.
Zhenyu MaoDepartment of Clinical Laboratory, Ningbo Mingzhou Hospital, Zhejiang, Ningbo, China.
Yanye TuDepartment of Clinical Laboratory, The Affiliated Li Huili Hospital of Ningbo University, Ningbo, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to clarify the drug resistance characteristics and genomic background of bile-derived NDM-1-producing Methods: A bile-derived LHL25108073- Results: This isolate was identified to be ST2281, a sequence type rarely reported across clinical, environmental, and agricultural sources, with a genome size of 4,885,524 bp and a GC content of 61.27%, carrying one chromosome (4,687,937 bp) and one drug-resistant plasmid (197,587 bp). A total of 58 high-confidence virulence genes were detected, covering common flagella, polar flagella, lateral flagella, type IV pili, Msh pili, type VI/II secretion system (T6SS/T2SS), heme-uptake systems, Endotoxins, and hemolysin, forming multiple pathogenic mechanisms. Among 14 drug resistance genes, the carbapenem-resistant NDM-1 gene was highly consistent with the genotype, only sensitive to a few drugs such as amikacin and aztreonam, based on the results of drug susceptibility tests. The drug-resistant plasmid could not autonomously conjugate and transfer due to the loss of the oriT site and was untypable by conventional plasmid typing. This plasmid shared 99-100% homology in the resistance core regions with two NDM-1-carrying Conclusion: This study characterizes the molecular profiles of an extraintestinal, bile-derived NDM-1-producing

Indexed as

Aeromonas caviaecarbapenem resistanceextraintestinal infectionNDM-1 resistance genewhole-genome sequencing

Identifiers

PMID42866320
PMCPMC13656038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.